Access in United Arab Emirates
Middle East ยท Tier 1
Regulatory framework
The UAE recognises a formal Named Patient / compassionate-use pathway via MOHAP and the Department of Health Abu Dhabi (DoH). Physicians apply on behalf of individual patients for drugs not registered in-country.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Typical timeline
We give you a written timeline estimate for your case before you commit. Timing depends on the specific drug, the clinical justification, and destination-regulator review pace.
What a typical process looks like
- Patient or physician submits a request with drug name and indication.
- We verify clinical appropriateness and document eligibility.
- Treating physician issues prescription and clinical justification.
- Country-specific regulatory documentation is prepared and submitted.
- Patient pre-pays; we source via DSCSA-compliant US wholesaler.
- Drug ships cold-chain to destination physician or hospital pharmacy.
- Physician receives, confirms storage, and begins treatment.
Popular drug requests from United Arab Emirates
Lenmeldy
Metachromatic leukodystrophy
Kresladi
Leukocyte adhesion deficiency I
Elevidys
Duchenne muscular dystrophy
Lyfgenia
Sickle cell disease
Zevaskyn
Recessive DEB
Skysona
Cerebral adrenoleukodystrophy
Casgevy
Sickle cell disease; transfusion-dependent beta-thalassemia
Ryoncil
Pediatric SR-aGvHD
Tecelra
Synovial sarcoma
Encelto
Macular telangiectasia type 2
Qfitlia
Hemophilia A/B prophylaxis
Vyjuvek
Dystrophic epidermolysis bullosa